

Sample Received: **March 19, 2026**COA Issued: **March 25, 2026**

## PRODUCT INFORMATION

Vendor:  
**Oasis Labs**Sample Name:  
**FOXO4-DRI 10mg**Sample Type:  
**White lyophilized powder**Lot Number:  
**262702**MW:  
**5358.05 g/mol**



## ANALYTICAL METHODS

**Identity:** Confirmed via MALDI-MS**Purity:** RP-HPLC (214 nm)**Content:** HPLC quantitation

## TEST RESULTS

Specification	Result	Method	Status
Identity: FOXO4-DRI	FOXO4-DRI	MALDI-MS	✓ Conforms
Content	10.82 mg	HPLC Quantitation	✓ Conforms
Overall Purity	99.7%	RP-HPLC (214 nm)	✓ Conforms

## ANALYTICAL DATA

HPLC Chromatogram (Retention Time: 6.40 min)**Certification:** This COA confirms that the tested material meets or exceeds Bioviridian's analytical quality specifications for peptide research use.Visit: <https://bioviridians.com/coa-search.html>*Shane Straight***Shane Straight, M.S.**  
Principal Chemist, Bioviridian Inc.Contact: [info@bioviridians.com](mailto:info@bioviridians.com)